New­ly ar­rived on Nas­daq, Po­sei­da qui­et­ly sig­nals a clin­i­cal hold trig­gered by a pa­tient death in PhI — shares crater

Just a few weeks af­ter kick­ing off their IPO in search of build­ing a next-gen CAR-T com­pa­ny, Po­sei­da Ther­a­peu­tics $PSTX finds it­self with a big set­back to nav­i­gate with their new in­vestors.

Some­time ear­li­er to­day the FDA slapped a full clin­i­cal hold on their Phase I study of their sec­ond au­tol­o­gous pro­gram for P-PS­MA-101 in metasta­t­ic cas­trate re­sis­tant prostate can­cer.

Ac­cord­ing to an SEC fil­ing, which hasn’t trig­gered a re­lease from the com­pa­ny, a pa­tient in the ear­ly study was hos­pi­tal­ized and then died of he­pat­ic fail­ure 17 days af­ter re­ceiv­ing their CAR-T.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER